基于卡巴拉汀的多靶点抗阿尔茨海默症药物的研究进展
Progress of Rivastigmine hybrids in multi-target drugs against Alzheimer's disease
作者：顾建荣;牛林徽;王柯人;柳文敏;桑志培;
Author：
收稿日期： 年卷（期）页码：2019,34(03):-200-208
期刊名称：华西药学杂志
Journal Name：WEST CHINA JOURNAL OF PHARMACEUTICAL SCIENCES
关键字：阿尔茨海默症;多靶点导向药物;司来吉兰-卡巴拉汀杂合体;金属离子络合剂-卡巴拉汀杂合体;多奈哌齐-卡巴拉汀杂合体;染料木素-卡巴拉汀杂合体;卡巴拉汀-姜黄素杂合体;灯盏乙素苷元-卡巴拉汀杂合体;查耳酮-卡巴拉汀杂合体;香豆素-卡巴拉汀杂合体
Key words：
基金项目：河南省高等学校重点科研资助项目(No.17B350002);;
南阳市基础与前沿技术研究计划资助项目(No.2017JCQY020、2017JCQY021)
中文摘要
阿尔茨海默症(Alzheimer’s disease,AD)是一种常见于老年人群的慢性、渐进性的神经退行性疾病。目前尚无有效的治疗药物,临床使用的单一靶点AD治疗药物仅能短期内局限性的改善AD症状,并不能有效地阻止和逆转该病的进程。鉴于AD复杂的网络病理特征,同时作用于多个AD相关靶点的单一化合物,即多靶点导向配体(multitargetdirected ligands,MTDLs)被认为是目前有效的治疗策略。卡巴拉汀是美国食品药品管理局批准的乙酰胆碱酯酶抑制剂,能显著地改善AD患者的认知功能和行为能力,氨基甲酸酯片段是其主要的药效团。现根据公开发表的文献,对基于卡巴拉汀的多靶点抗阿尔茨海默病药物的研究进行了综述,期望为多靶点抗AD药物研究提供借鉴。
参考文献
[1]Alzheimer’s Disease International.The Global Impact of Dementia[C].World Alzheimer Report,2015.
[2]张丽景,汪晨净,杨战利.白芦藜醇防治阿尔茨海默病的研究进展[J].华西药学杂志,2018,33(5):561-564.
[3]Citron M.Alzheimer’s disease:Strategies for disease modification[J].Nat Rev Drug Discov,2010,9(5):387-398.
[4]Fang J,Li Y,Liu R,et al.Discovery of multitarget-directed ligands against Alzheimer's disease through systematic prediction of chemical-protein interactions[J].J Chem Inf Model,2015,55(1):149-164.
[5]Liu K,Lin HH,Pi R,et al.Research and development of anti-Alzheimer's disease drugs:An update from the perspective of technology flows[J].Expert Opin Ther Pat,2018,28(4):341-350.
[6]De Freitas SM,Dias KST,Gontijo VS,et al.Multi-target directed drugs as a modern approach for drug design towards Alzheimer's disease:An update[J].Curr Med Chem,2018,DOI:10.2174/0929867325666180111101843.
[7]Hane FT,Robinson M,Lee BY,et al.Recent progress in Alzheimer's disease research,Part 3:Diagnosis and treatment[J].J Alzheimers Dis,2017,57(3):645-665.
[8]Khoury R,Rajamanickam J,Grossberg GT.An update on the safety of current therapies for Alzheimer's disease:Focus on rivastigmine[J].Ther Adv Drug Saf,2018,9(3):171-178.
[9]Sterling J,Herzig Y,Goren T,et al.Novel dual inhibitors of AChE and MAO derived from hydroxy aminoindan and phenethylamine as potential treatment for Alzheimer’s disease[J].J Med Chem,2002,45(24):5260-5279.
[10]Denya I,Malan SF,Enogieru AB,et al.Design,synthesis and evaluation of indole derivatives as multifunctional agents against Alzheimer's disease[J].Medchemcomm,2018,9(2):357-370.
[11]Zheng H,Youdim MB,Fridkin M.Selective acetylcholinesterase inhibitor activated by acetylcholinesterase releases an activechelator with neurorescuing and anti-amyloid activities[J].ACS Chem Neurosci,2010,1(11):737-746.
[12]Zheng H,Youdim MB,Fridkin M.Site-activated chelators targeting acetylcholinesterase and monoamine oxidase for Alzheimer's therapy[J].ACS Chem Biol,2010,5(6):603-610.
[13]Xie Q,Zheng Z,Shao B,et al.Pharmacophore-based design and discovery of(-)-meptazinol carbamates as dual modulators of cholinesterase and amyloidogenesis[J].J Enzyme Inhib Med Chem,2017,32(1):659-671.
[14]Bajda M,ttka K,Hebda M,et al.Novel carbamate derivatives as selective butyrylcholinesterase inhibitors[J].Bioorg Chem,2018,78(3):29-38.
[15]VorcˇákováK,MájekováM,HorákováE,et al.Synthesis and characterization of new inhibitors of cholinesterases based on N-phenyl carbamates:In vitro study of inhibitory effect,type of inhibition,lipophilicity and molecular docking[J].Bioorg Chem,2018,78(3):280-289.
[16]Yanovsky I,Finkin-Groner E,Zaikin A,et al.Carbamate derivatives of indolines as cholinesterase inhibitors and antioxidants for the treatment of Alzheimer’s disease[J].J Med Chem,2012,55(23):10700-10715.
[17]Qiang X,Yuan W,Sang Z,et al.Synthesis and biological evaluation of genistein carbamate derivatives[J].Chin J Org Chem,2013,3(10):621-629.
[18]Li Y,Peng P,Tang L,et al.Design,synthesis and evaluation of rivastigmine and curcumin hybrids as site-activated multitarget-directed ligands for Alzheimer’s disease therapy[J].Bioorg Med Chem,2014,22(17):4717-4725.
[19]Sang Z,Li Y,Qiang X,et al.Multifunctional scutellarinrivastigmine hybrids with cholinergic,antioxidant,biometal chelating and neuroprotective properties for the treatment of Alzheimer's disease[J].Bioorg Med Chem,2015,23(4):668-680.
[20]Sang ZP,Qiang XM,Li Y,et al.Design,synthesis,and biological evaluation of scutellarein carbamate derivatives as potential multifunctional agents for the treatment of Alzheimer's disease[J].Chem Biol Drug Des,2015,86(5):1168-1177.
[21]Chen YP,Zhang ZY,Li YP,et al.Syntheses and evaluation of novel isoliquiritigenin derivatives as potential dual inhibitors for amyloid-beta aggregation and 5-lipoxygenase[J].Eur JMed Chem,2013,66(5):22-31.
[22]Wang L,Wang Y,Tian Y,et al.Design,synthesis,biological evaluation,and molecular modeling studies of chalcone-rivastigmine hybrids as cholinesterase inhibitors[J].Bioorg Med Chem,2017,25(1):360-371.
[23]Xiao G,Li Y,Qiang X,et al.Design,synthesis and biological evaluation of 4’-aminochalcone-rivastigmine hybrids as multifunctional agents for the treatment of Alzheimer’s disease[J].Bioorg Med Chem,2017,25(3):1030-1041.
[24]Belluti F,Rampa A,Piazzi L,et al.Cholinesterase inhibitors:xanthostigmine derivatives blocking the acetylcholinesteraseinduced beta-amyloid aggregation[J].J Med Chem,2005,48(13):4444-4456.
[25]Rampa A,Montanari S,Pruccoli L,et al.Chalcone-based carbamates for Alzheimer's disease treatment[J].Future Med Chem,2017,9(8),749-764.
[26]Chen Z,Digiacomo M,Tu Y,et al.Discovery of novel rivastigmine-hydroxycinnamic acid hybrids as multi-targeted agents for Alzheimer's disease[J].Eur J Med Chem,2017,125(9):784-792.
[27]Nesi G,Chen Q,Sestito S,et al.Nature-based molecules combined with rivastigmine:A symbiotic approach for the synthesis of new agents against Alzheimer's disease[J].Eur JMed Chem,2017,141(10):232-239.
[28]Kurt BZ,Gazioglu I,Dag A,et al.Synthesis,anticholinesterase activity and molecular modeling study of novel carbamatesubstituted thymol/carvacrol derivatives[J].Bioorg Med Chem,2017,25(4):1352-1363.
[29]Jiang N,Huang Q,Liu J,et al.Design,synthesis and biological evaluation of new new coumarin-dithiocarbamate hybrids asmultifunctional agents for the treatment of Alzheimer's disease[J].Eur J Med Chem.2018,146(1):287-298.
[30]Chen C,Wang Z,Zhang Z,et al.The prodrug of 7,8-dihydroxyflavone development and therapeutic efficacy for treating Alzheimer's disease[J].Proc Natl Acad Sci USA,2018,115(3):578-583.
【关闭】
